Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D5R6AG
|
|||
| Drug Name |
ATI-2173
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Hepatitis B [ICD-11: 1E51; ICD-10: B18.1] | Phase 2 | [1] | |
| Company |
Antios Therapeutics
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Hepatitis B virus Polymerase (HBV P) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04847440) A Study of Safety and Efficacy of ATI-2173 in Combination With Tenofovir Disoproxil Fumarate in Subjects With Chronic Hepatitis B Virus Infection and in Subjects With Hepatitis D Virus Coinfection. U.S. National Institutes of Health. | |||
| REF 2 | ATI-2173, a Novel Liver-Targeted Non-Chain-Terminating Nucleotide for Hepatitis B Virus Cure Regimens. Antimicrob Agents Chemother. 2020 Aug 20;64(9):e00836-20. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.